EREupa Ray

Eupa Ray

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eupa Ray has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Kalpesh Vaghasiya

    Institute of Nano Science and Technology (INST), Phase-10, Sector-64, Mohali, Punjab 160062, India

    3 shared publications
  • Rahul Kumar Verma

    Pharmaceutical Nanotechnology lab, Institute of Nano Science and Technology (INST), Sector-81, Mohali, Punjab 160062, India

    3 shared publications
  • Ankur Sharma

    Institute of Nano Science and Technology (INST), Punjab, India

    2 shared publications
  • Krishna Jadhav

    Pharmaceutical Nanotechnology Lab, Chemical Biology Unit, Institute of Nano Science and Technology (INST), Sector-82, Mohali, Punjab, 160062, India

    2 shared publications
  • Raghuraj Singh

    Pharmaceutical Nanotechnology Lab, Chemical Biology Unit, Institute of Nano Science and Technology (INST), Sector-82, Mohali, Punjab, 160062, India

    2 shared publications
  • Amit Kumar Singh

    ICMR-National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, Uttar Pradesh, India

    1 shared publication

Latest Publications

  • New Generation Smart Drug Delivery Systems for Rheumatoid Arthritis

    by Raghuraj Singh, Krishna Jadhav, Kalpesh Vaghasiya, Eupa Ray, Rahul Shukla, Rahul Kumar Verma

    Rheumatoid arthritis (RA) is the most common form of the chronic inflammatory autoimmune disease characterized by chronic synovitis, synovial proliferation, and cellular infiltration. Further, it leads to bone erosion, destruction of articular cartilage, intense joint pain, swelling, and a high rate of disability, causing an immense load on human health. If the disease is identified early on, and the patient has continuous and timely treatment, many patients can achieve remission. Although research in RA has made considerable progress, conventional therapies are still the most popular treatment options for most people with RA. But, conventional therapies are hampered by various drawbacks, including higher doses, low solubility and permeability, poor bioavailability, a high level of first-pass metabolism, adaptive treatment tolerance (ATT), and long-term drug use. These drawbacks can result in severe side effects and drug toxicity in patients. Advances in polymer science and the application of nanotechnology in drug delivery systems have provided new possibilities in the treatment of RA by developing new-generation smart drug delivery systems (SDDSs). The shortcomings of non-specific drug distribution and uncontrollable drug release by traditional delivery systems have motivated the creation of next-generation SDDSs. These new smart drug delivery treatment methods have significantly changed the course of RA. Such systems can improve drug delivery by virtue of their multi-functionality and targeting capabilities. The ultimate objective of next-generation SDDSs is to deliver medication at the optimal time with precise dosage and efficiency and specificity to the targeted site (such as cells, tissues, and organs), which can aid patients to adhere better to their therapy. This review highlights and discusses the various next-generation SDDSs along with the conventional treatment options available for RA management.


  • Systematic development and optimization of spray-dried Quercetin-HP-β-cyclodextrin microparticles for DPI-based therapy of lung cancer

    by Kalpesh Vaghasiya, Eupa Ray, Ankur Sharma, Raghuraj Singh, Krishna Jadhav, Rehan Khan, Om Prakash Katare, Rahul Kumar Verma


  • Targeted Pulmonary Delivery of the Green Tea Polyphenol Epigallocatechin Gallate Controls the Growth of Mycobacterium tuberculosis by Enhancing the Autophagy and Suppressing Bacterial Burden

    by Ankur Sharma, Kalpesh Vaghasiya, Eupa Ray, Pushpa Gupta, Umesh Datta Gupta, Amit Kumar Singh, Rahul Kumar Verma

    Growing rates of tuberculosis (TB) superbugs are alarming, which has hampered the progress made to-date to control this infectious disease, and new drug candidates are few. Epigallocatechin gallate (EGCG), a major polyphenolic compound from green tea extract, shows powerful efficacy against TB bacteria in in vitro studies. However, the therapeutic efficacy of the molecule is limited due to poor pharmacokinetics and low bioavailability following oral administration. Aiming to improve the treatment outcomes of EGCG therapy, we investigated whether encapsulation and pulmonary delivery of the molecule would allow the direct targeting of the site of infection without compromising the activity. Microencapsulation of EGCG was realized by scalable spray-freeze-drying (SFD) technology, forming free-flowing micrometer-sized microspheres (epigallocatechin-3-gallate-loaded trehalose microspheres, EGCG-t-MS) of trehalose sugar. These porous microspheres exhibited appropriate aerodynamic parameters and high encapsulation efficiencies. In vitro studies demonstrated that EGCG-t-MS exhibited dose- and time-dependent killing of TB bacteria inside mouse macrophages by cellular mechanisms of lysosome acidification and autophagy induction. In a preclinical study on TB-infected Balb/c mice model (4 weeks of infection), we demonstrate that the microencapsulated EGCG, administered 5 days/week for 6 weeks by pulmonary delivery, showed exceptional efficacy compared to oral treatment of free drug. This treatment approach exhibited therapeutic outcomes by resolution of inflammation in the infected lungs and significant reduction (P < 0.05) in bacterial burden (up to ∼2.54 Log10 CFU) compared to untreated control and orally treated mice groups. No pathological granulomas, lesions, and inflammation were observed in the histopathological investigation, compared to untreated controls. The encouraging results of the study may pave the avenues for future use of EGCG in TB therapeutics by targeted pulmonary delivery and lead to its translational success.